DE69807768T2 - Rapamycin enthaltende Formulierungen zur oralen Verabreichung - Google Patents

Rapamycin enthaltende Formulierungen zur oralen Verabreichung

Info

Publication number
DE69807768T2
DE69807768T2 DE69807768T DE69807768T DE69807768T2 DE 69807768 T2 DE69807768 T2 DE 69807768T2 DE 69807768 T DE69807768 T DE 69807768T DE 69807768 T DE69807768 T DE 69807768T DE 69807768 T2 DE69807768 T2 DE 69807768T2
Authority
DE
Germany
Prior art keywords
rapamycin
oral administration
containing formulations
formulations
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69807768T
Other languages
English (en)
Other versions
DE69807768D1 (de
Inventor
Arwinder S Nagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE69807768D1 publication Critical patent/DE69807768D1/de
Publication of DE69807768T2 publication Critical patent/DE69807768T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
DE69807768T 1997-03-14 1998-03-09 Rapamycin enthaltende Formulierungen zur oralen Verabreichung Expired - Lifetime DE69807768T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81501597A 1997-03-14 1997-03-14

Publications (2)

Publication Number Publication Date
DE69807768D1 DE69807768D1 (de) 2002-10-17
DE69807768T2 true DE69807768T2 (de) 2003-02-06

Family

ID=25216622

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69807768T Expired - Lifetime DE69807768T2 (de) 1997-03-14 1998-03-09 Rapamycin enthaltende Formulierungen zur oralen Verabreichung

Country Status (25)

Country Link
EP (1) EP0868911B1 (de)
JP (2) JP4616426B2 (de)
KR (1) KR100513919B1 (de)
CN (1) CN1140268C (de)
AR (1) AR012069A1 (de)
AT (1) ATE223705T1 (de)
AU (1) AU723943B2 (de)
BR (1) BR9801120B1 (de)
CA (1) CA2230748C (de)
CY (1) CY2313B1 (de)
CZ (1) CZ292949B6 (de)
DE (1) DE69807768T2 (de)
DK (1) DK0868911T3 (de)
ES (1) ES2183287T3 (de)
HK (1) HK1015677A1 (de)
HU (1) HU224701B1 (de)
IL (1) IL123525A (de)
NZ (1) NZ329976A (de)
PT (1) PT868911E (de)
RU (1) RU2220714C2 (de)
SG (1) SG63824A1 (de)
SI (1) SI0868911T1 (de)
TW (1) TW550091B (de)
UA (1) UA56143C2 (de)
ZA (1) ZA982112B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
PT994697E (pt) * 1997-06-13 2005-02-28 Wyeth Corp Formulacoes de rapamicina para administracao oral
JP4969747B2 (ja) * 2001-01-19 2012-07-04 武田薬品工業株式会社 錠剤フィルムコーティング用組成物
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
US20080275076A1 (en) * 2005-03-08 2008-11-06 Per Holm Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof
CN102579387A (zh) * 2006-09-26 2012-07-18 诺瓦提斯公司 包含s1p调节剂的药物组合物
RU2009116424A (ru) * 2006-11-07 2010-12-20 Вайет (Us) Сахаросодержащие покрытия и способы их получения
EP1938800A1 (de) * 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus-Nanodispersion
EP1952807A1 (de) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimusformulierung
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN110585159B (zh) * 2019-09-12 2021-11-02 杭州华东医药集团新药研究院有限公司 一种含有西罗莫司的片剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2278780B (en) * 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.

Also Published As

Publication number Publication date
HU9800573D0 (en) 1998-05-28
TW550091B (en) 2003-09-01
JPH10259131A (ja) 1998-09-29
EP0868911A3 (de) 2000-12-06
JP4616426B2 (ja) 2011-01-19
ZA982112B (en) 1999-09-13
CZ292949B6 (cs) 2004-01-14
JP2009298823A (ja) 2009-12-24
AU5838398A (en) 1998-09-17
AU723943B2 (en) 2000-09-07
RU2220714C2 (ru) 2004-01-10
CN1197639A (zh) 1998-11-04
SI0868911T1 (en) 2002-12-31
CA2230748C (en) 2010-08-03
KR19980080222A (ko) 1998-11-25
KR100513919B1 (ko) 2006-02-28
AR012069A1 (es) 2000-09-27
BR9801120B1 (pt) 2009-12-01
HK1015677A1 (en) 1999-10-22
DE69807768D1 (de) 2002-10-17
HUP9800573A2 (hu) 1999-06-28
UA56143C2 (uk) 2003-05-15
IL123525A (en) 2002-03-10
ATE223705T1 (de) 2002-09-15
EP0868911B1 (de) 2002-09-11
NZ329976A (en) 1999-10-28
SG63824A1 (en) 1999-03-30
BR9801120A (pt) 2000-01-11
ES2183287T3 (es) 2003-03-16
IL123525A0 (en) 1998-10-30
CY2313B1 (en) 2003-11-14
EP0868911A2 (de) 1998-10-07
HUP9800573A3 (en) 2000-01-28
CZ77198A3 (cs) 1998-09-16
DK0868911T3 (da) 2003-01-20
CA2230748A1 (en) 1998-09-14
PT868911E (pt) 2002-12-31
HU224701B1 (en) 2006-01-30
CN1140268C (zh) 2004-03-03

Similar Documents

Publication Publication Date Title
ID23299A (id) Formulasi-formulasi farmasi
DE10199046I2 (de) Rapamycin-Zubereitungen zur oralen Verabreichung
BR9708785A (pt) Preparado farmaceutico oral contendo ibandronato
NO993096D0 (no) Orale cyklosporinformuleringer
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
DE69807768T2 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
ATE309838T1 (de) Pharmazeutisches implantat
ID16781A (id) Formulasi-formulasi farmasi
ATE283687T1 (de) Rapamycin-formulierungen zur oralen verabreichung
DE29703459U1 (de) Dental-Artikulator
DE29723220U1 (de) Mittel zur peroralen Verabreichung
DE29703380U1 (de) Multivitaminpräparat zur oralen Verabreichung
GB9828205D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9813452D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations
GB9826392D0 (en) Pharmaceutical formulations
GB9825117D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9807556D0 (en) Pharmaceutical formulations
IT1302626B1 (it) Veicolante per formulazioni orali
SE9502453D0 (sv) Drug formulations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition